{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:17:04Z","timestamp":1786119424870,"version":"build-2736575974"},"reference-count":17,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,1]]},"DOI":"10.1097\/wnf.0b013e3181c47168","type":"journal-article","created":{"date-parts":[[2010,2,25]],"date-time":"2010-02-25T01:52:11Z","timestamp":1267062731000},"page":"14-16","source":"Crossref","is-referenced-by-count":42,"title":["Current Use of Clozapine in Parkinson Disease and Related Disorders"],"prefix":"10.1097","volume":"33","author":[{"given":"Alissa A.","family":"Thomas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph H.","family":"Friedman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"issue":"2","key":"R1-4-20210203","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/1531-8257(200003)15:2<201::AID-MDS1001>3.0.CO;2-D","article-title":"Atypical antipsychotics in the treatment of drug-induced psychosis in Parkinson's disease.","volume":"15","author":"Friedman","year":"2000","journal-title":"Mov Disord"},{"key":"R2-4-20210203","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S0079-6123(08)00923-0","article-title":"Parkinson's disease-opportunities for novel therapeutics to reduce the problems of levodopa therapy.","volume":"172","author":"Fox","year":"2008","journal-title":"Prog Brain Res"},{"key":"R3-4-20210203","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1136\/jnnp.2008.152579","article-title":"When a Parkinson's disease patient starts to hallucinate.","volume":"8","author":"Poewe","year":"2008","journal-title":"Pract Neurol"},{"key":"R4-4-20210203","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1002\/mds.20474","article-title":"Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson's disease.","volume":"20","author":"Ondo","year":"2005","journal-title":"Mov Disord"},{"key":"R5-4-20210203","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1002\/mds.21116","article-title":"Effect of quetiapine in psychotic Parkinson's disease patients: a double-blind labeled study of 3 months duration.","volume":"22","author":"Rabey","year":"2007","journal-title":"Mov Disord"},{"issue":"10","key":"R6-4-20210203","first-page":"757","article-title":"The Parkinson Study Group.","volume":"340","year":"1999","journal-title":"N Engl J Med"},{"key":"R7-4-20210203","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1136\/jnnp.2003.029868","article-title":"Clozapine in drug induced psychosis in Parkinson's disease: a randomised, placebo controlled study with open follow up.","volume":"75","author":"Pollack","year":"2004","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R8-4-20210203","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1212\/WNL.48.4.1077","article-title":"Benztropine versus clozapine for the treatment of tremor in Parkinson's disease.","volume":"4","author":"Friedman","year":"1997","journal-title":"Neurology"},{"issue":"7","key":"R9-4-20210203","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1002\/mds.20051","article-title":"Long-term outcome of clozapine use for psychosis in parkinsonian patients.","volume":"19","author":"Fernandez","year":"2004","journal-title":"Mov Disord"},{"issue":"7","key":"R10-4-20210203","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1212\/01.wnl.0000215428.46057.3d","article-title":"Quality Standards Subcommittee of the American Academy of Neurology. Practice parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology.","volume":"66","author":"Miyasaki","year":"2006","journal-title":"Neurology"},{"key":"R11-4-20210203","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1212\/01.wnl.0000229933.91780.67","article-title":"Atypical antipsychotics and the \"black box\" warning.","volume":"67","author":"Friedman","year":"2006","journal-title":"Neurology"},{"key":"R12-4-20210203","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S1474-4422(08)70295-3","article-title":"DART-AD investigators. The dementia antipsychotic withdrawal trial (DART-AD): long-term follow up of randomized placebo-controlled trial.","volume":"8","author":"Ballard","year":"2009","journal-title":"Lancet Neurol"},{"key":"R13-4-20210203","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1056\/NEJMoa0806994","article-title":"Atypical antipsychotic drugs and the risk of sudden cardiac death.","volume":"360","author":"Ray","year":"2009","journal-title":"N Eng J Med"},{"issue":"3-B","key":"R14-4-20210203","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1590\/S0004-282X2008000500001","article-title":"Use of clozapine in Brazilian patients with Parkinson's disease.","volume":"66","author":"Gomide","year":"2008","journal-title":"Arq Neuropsiquiatr"},{"issue":"2","key":"R15-4-20210203","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/mds.870070205","article-title":"Clozapine prevents recurrence of psychosis in Parkinson's disease.","volume":"7","author":"Factor","year":"1992","journal-title":"Mov Disord"},{"issue":"1","key":"R16-4-20210203","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/1531-8257(200101)16:1<135::AID-MDS1006>3.0.CO;2-Q","article-title":"The Parkinson Study Group. Clozapine for the treatment of drug-induced psychosis in Parkinson's disease: results of the 12 week open label extension in the PSYCLOPS trial.","volume":"16","author":"Factor","year":"2001","journal-title":"Mov Disord"},{"key":"R17-4-20210203","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1002\/mds.870090406","article-title":"Suppression of dyskinesias in advanced Parkinson's disease: moderate daily clozapine doses provide long-term dyskinesia reduction.","volume":"9","author":"Bennett","year":"1994","journal-title":"Mov Disord"}],"container-title":["Clinical Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00002826-201001000-00004","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:12:30Z","timestamp":1786039950000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00002826-201001000-00004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,1]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1097\/wnf.0b013e3181c47168","relation":{},"ISSN":["0362-5664"],"issn-type":[{"value":"0362-5664","type":"print"}],"subject":[],"published":{"date-parts":[[2010,1]]}}}